Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review Neasa KellyAndrew KilmartinJuliette O’Connell Review Open access 31 August 2022 Pages: 1711 - 1725
Real-world comparison of fidaxomicin versus vancomycin or metronidazole in the treatment of Clostridium difficile infection: a systematic review and meta-analysis Jianfeng DaiJing GongRui Guo Review 03 September 2022 Pages: 1727 - 1737
Neonatal outcomes after gamma-aminobutyric acid analog use during pregnancy: a meta-analysis of cohort studies Xi-long JinBao-hua SongGuang-biao Huang Review 10 September 2022 Pages: 1739 - 1747
Daridorexant for the treatment of insomnia disorder: findings and implications Jéssica Barreto Ribeiro dos SantosMichael Ruberson Ribeiro da Silva Review 13 September 2022 Pages: 1749 - 1761
Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review Dylan van de VussePaola MianJorie Versmissen Review Open access 15 September 2022 Pages: 1763 - 1776
Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis Xiaomei WangDemei ZhangXueya Guo Review 22 September 2022 Pages: 1777 - 1790
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic Selena RussoMarco BaniMaria Grazia Strepparava Clinical Trial Open access 14 September 2022 Pages: 1791 - 1800
The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study Mohamed Nabil ElshafeiYahia ImamMohammed Ibn-Masoud Danjuma Clinical Trial Open access 19 September 2022 Pages: 1801 - 1811
Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials Paulo Ricardo Martins-FilhoEdmundo Marques do Nascimento-JúniorLis Campos Ferreira Research 06 September 2022 Pages: 1813 - 1821
Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects Katsuyuki MuraseLucy LeeMartin Thoolen Research 27 September 2022 Pages: 1823 - 1831
Use of a long-acting substitute in detoxification from benzodiazepines: safety (accumulation) problems and proposed mitigation procedure Anna Basińska-Szafrańska Pharmacokinetics and Disposition Open access 17 September 2022 Pages: 1833 - 1841
Simulations of topiramate dosage recommendations for poor compliance events Janthima MethaneethornWanaporn Charoenchokthavee Pharmacokinetics and Disposition 19 September 2022 Pages: 1843 - 1850
Higher FORTA (Fit fOR The Aged) scores are associated with poor functional outcomes, dementia, and mortality in older people Farhad PazanHanna BreunigMartin Wehling Pharmacoepidemiology and Prescription Open access 27 September 2022 Pages: 1851 - 1859
Students’ guide to documentation in clinical trials Johannes HeckAnn-Kathrin RathJacobus J. Bosch Perspective Open access 30 September 2022 Pages: 1861 - 1862
Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time Norint P. TungJoseph D. Ma Perspective Open access 13 September 2022 Pages: 1863 - 1864
Response to: “Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time” Kine Eide KvitneKristine HoleIda Robertsen Correspondence Open access 13 September 2022 Pages: 1865 - 1866